Autores
Jasvinder A Singh, Kenneth G Saag, S Louis Bridges Jr, Elie A Akl, Raveendhara R Bannuru, Matthew C Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H Shmerling, Jeffrey R Curtis, Daniel E Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L Matteson, John T Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E William St. Clair, Elizabeth Tindall, Amy S Miller, Timothy McAlindon
Fecha de publicación
2016/1
Origen
Arthritis & rheumatology
Volumen
68
Número
1
Páginas
1-26
Descripción
Objective
To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA).
Methods
We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.
Results
The guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib …
Artículos de Google Académico
JA Singh, KG Saag, SL Bridges Jr, EA Akl, RR Bannuru… - Arthritis & rheumatology, 2016